MX2010000997A - Combinaciones farmaceuticas que comprenden un inhibidor de tirosina cinasa y un anticuerpo contra integrina alfa 1 beta 5 (cd49b). - Google Patents

Combinaciones farmaceuticas que comprenden un inhibidor de tirosina cinasa y un anticuerpo contra integrina alfa 1 beta 5 (cd49b).

Info

Publication number
MX2010000997A
MX2010000997A MX2010000997A MX2010000997A MX2010000997A MX 2010000997 A MX2010000997 A MX 2010000997A MX 2010000997 A MX2010000997 A MX 2010000997A MX 2010000997 A MX2010000997 A MX 2010000997A MX 2010000997 A MX2010000997 A MX 2010000997A
Authority
MX
Mexico
Prior art keywords
tyrosine kinase
kinase inhibitor
pharmaceutical combinations
cd49e
beta
Prior art date
Application number
MX2010000997A
Other languages
English (en)
Inventor
Vanitha Ramakrishnan
Vinay Bhaskar
Original Assignee
Facet Biotech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Facet Biotech Corp filed Critical Facet Biotech Corp
Publication of MX2010000997A publication Critical patent/MX2010000997A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Las combinaciones farmacéuticas que comprenden un antagonista de a5ß1 en combinación con un inhibidor de tirosina cinasa. En algunas modalidades, el antagonista de a5ß1 es volociximab. En algunas modalidades, el inhibidor de tirosina cinasa es sunitinib o una sal farmacéuticamente aceptable del mismo. La invención también se refiere a métodos para tratar cáncer administrando las combinaciones farmacéuticas a un sujeto.
MX2010000997A 2007-07-27 2008-07-28 Combinaciones farmaceuticas que comprenden un inhibidor de tirosina cinasa y un anticuerpo contra integrina alfa 1 beta 5 (cd49b). MX2010000997A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95232807P 2007-07-27 2007-07-27
PCT/US2008/071379 WO2009018226A2 (en) 2007-07-27 2008-07-28 Pharmaceutical combinations comprising a tyrosine kinase inhibitor and an antibody against integrin alpha 1 beta 5 (cd49e)

Publications (1)

Publication Number Publication Date
MX2010000997A true MX2010000997A (es) 2010-03-31

Family

ID=40291258

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010000997A MX2010000997A (es) 2007-07-27 2008-07-28 Combinaciones farmaceuticas que comprenden un inhibidor de tirosina cinasa y un anticuerpo contra integrina alfa 1 beta 5 (cd49b).

Country Status (9)

Country Link
US (1) US20090041767A1 (es)
EP (1) EP2193148A2 (es)
JP (1) JP2010534685A (es)
KR (1) KR20100040877A (es)
AU (1) AU2008282331A1 (es)
BR (1) BRPI0813630A2 (es)
CA (1) CA2694644A1 (es)
MX (1) MX2010000997A (es)
WO (1) WO2009018226A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2255792A1 (en) * 2009-05-20 2010-12-01 Ratiopharm GmbH Pharmaceutical compositions for N-[2-(Diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1H-pyrrole-3-carboxamide
EP2484678B1 (en) * 2009-09-28 2015-01-21 Qilu Pharmaceutical Co., Ltd 4-(substituted anilino)quinazoline derivatives as tyrosine kinase inhibitors
US20140079637A1 (en) * 2011-03-23 2014-03-20 The Regents Of The University Of California Methods and compositions for improving antiangiogenic therapy with anti-integrins
MX2014009898A (es) * 2012-02-16 2015-07-06 Capnia Inc Dispensador de gas con boquilla de difusion.
CN103656656A (zh) * 2013-12-18 2014-03-26 北京科源创欣科技有限公司 甲苯磺酸索拉非尼药物组合物及制备方法
AU2016311298A1 (en) 2015-08-25 2018-02-08 Histide Ag Compounds for inducing tissue formation and uses thereof
WO2017046229A1 (en) * 2015-09-17 2017-03-23 Histide Ag Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof
US20190330290A1 (en) * 2015-09-17 2019-10-31 Histide Ag Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof
AU2016323407A1 (en) * 2015-09-17 2018-04-19 Histide Ag Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704366A (en) * 1984-06-22 1987-11-03 Bio-Rad Laboratories, Inc. Process for binding IgG to protein A
JPS61134325A (ja) * 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4801687A (en) * 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
SK281142B6 (sk) * 1991-03-06 2000-12-11 Merck Patent Gesellschaft Mit Beschr�Nkter Haftung Humanizovaná monoklonálna protilátka, expresné vektory a farmaceutický prostriedok
AU669124B2 (en) * 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
GB9125979D0 (en) * 1991-12-06 1992-02-05 Wellcome Found Antibody
SG52215A1 (en) * 1992-02-19 1998-09-28 Schering Corp Cloning and expresssion of humanized monoclonal antibodies against human interleukin-4
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
JP3490443B2 (ja) * 1992-10-29 2004-01-26 ジ・オーストラリアン・ナショナル・ユニバーシティ 血管形成阻害性抗体
US5536814A (en) * 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
US5705154A (en) * 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US5922676A (en) * 1996-09-20 1999-07-13 The Burnham Institute Methods of inhibiting cancer by using superfibronectin
US5846536A (en) * 1996-10-04 1998-12-08 The Regents Of The University Of California Restoration of normal phenotype in cancer cells
US6852318B1 (en) * 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
US20040259152A1 (en) * 2000-02-22 2004-12-23 Richard Murray Novel methods of diagnosing and screening for modulators of tissue remodeling and treating related diseases
ES2387985T3 (es) * 2002-11-26 2012-10-05 Abbott Biotherapeutics Corp. Anticuerpos quiméricos y humanizados de integrina alfa 5 beta 1 que modulan la angiogénesis
US7276589B2 (en) * 2002-11-26 2007-10-02 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
WO2004089988A2 (en) * 2003-04-03 2004-10-21 Protein Design Labs, Inc Inhibitors of integrin alpha5beta1 and their use for the control of tissue granulation
NZ549893A (en) * 2004-03-24 2010-05-28 Facet Biotech Corp Use of anti-alpha5beta1 antibodiesin a stabilising solution to inhibit cancer cell proliferation
US7908091B2 (en) * 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
NZ615012A (en) * 2006-03-21 2015-11-27 Genentech Inc Combinatorial therapy involving alpha5beta1 antagonists
US7612178B2 (en) * 2006-03-28 2009-11-03 Biogen Idec Ma Inc Anti-IGF-1R antibodies and uses thereof

Also Published As

Publication number Publication date
JP2010534685A (ja) 2010-11-11
KR20100040877A (ko) 2010-04-21
WO2009018226A2 (en) 2009-02-05
CA2694644A1 (en) 2009-02-05
AU2008282331A1 (en) 2009-02-05
WO2009018226A3 (en) 2009-04-02
BRPI0813630A2 (pt) 2019-09-24
US20090041767A1 (en) 2009-02-12
EP2193148A2 (en) 2010-06-09

Similar Documents

Publication Publication Date Title
MX2010000997A (es) Combinaciones farmaceuticas que comprenden un inhibidor de tirosina cinasa y un anticuerpo contra integrina alfa 1 beta 5 (cd49b).
NZ617196A (en) Activin-actrii antagonists and uses for increasing red blood cell levels
CL2007002017A1 (es) Compuestos derivados de [4,5']-bipirimidinil-6,4'-diamina; composicion farmaceutica; y uso como inhibidor de la actividad de cinasa en cancer de vejiga, cancer cervical y mieloma multiple.
TW200733971A (en) CGRP peptide antagonists and conjugates
TW201129378A (en) Materials and methods for treating or preventing HER-3 associated diseases
TN2009000444A1 (en) Combination therapy with a compound acting as a plateletadp receptor inhibitor
MY150697A (en) Methods of treating cancer using pyridopyrimdinone inhibitors of p13k alpha
MX2009003038A (es) Derivados de quinazolinona 5-sustituidos como agentes antitumorales.
TR201900306T4 (tr) Mek inhibitörlerini kullanma yöntemleri.
MY154909A (en) Novel thiophene derivatives
IL192948A0 (en) Novel pyridine derivatives
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
UA97795C2 (uk) Дейтеровані похідні катехоламіну і медикаменти, що містять згадані сполуки
PL1909843T3 (pl) Przeciwnowotworowe biokoniugaty kwasu hialuronowego lub jego pochodne otrzymane przez pośrednie sprzęganie chemiczne i ich zastosowanie w dziedzinie farmacji
BRPI0908635B8 (pt) composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica
UA101313C2 (uk) Щотижневе введення інгібіторів дипептидилпептидази
MX2010001574A (es) Ligandos del receptor cannabinoide.
UA107779C2 (en) Method of synthetic 7,8-dimethoxy-1,3-dihydro-2h-3-benzazepin-2-one and use in the synthesis ivabradynu and its addition salts with pharmaceutically acceptable acid
MXPA05011858A (es) Agentes terapeuticos que comprenden un agente antiagiongenico en combinacion con un inhibidor src y su uso terapeutico.
TW200628171A (en) Compounds for myocardial perfusion imaging
MX2021004883A (es) Metodos y composiciones para tratar apnea del sue?o.
MX2008013017A (es) Tratamiento de malignidades hematologicas con fts y un inhibidor de tirosina cinasa de bcr-abl.
SG162766A1 (en) Benzooxazole-2-on derivatives as lipase and phospholipase inhibitors
RS54140B1 (en) USE OF 24-ORDER
RS51211B (sr) Primena formulacija koje sadrže kapa-opioid receptor-agoniste za tretman disocijativnih poremećaja

Legal Events

Date Code Title Description
FA Abandonment or withdrawal